|
09 Apr 2019 |
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
|
|
09 Apr 2019 |
Daiichi Sankyo’s EZH1/2 Dual Inhibitor Valemetostat (DS-3201) Receives SAKIGAKE Designation for Treatment of Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from Japan MHLW
|
|
08 Apr 2019 |
Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics
|
|
08 Apr 2019 |
Ascentage Pharma Announces Clinical Collaboration with Junshi Bioscience to Evaluate the Combination of APG-1387 and Toripalimab in Treating Cancers
|
|
08 Apr 2019 |
Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial
|
|
08 Apr 2019 |
United Therapeutics Announces BEAT Study of Esuberaprost Does Not Meet Primary Endpoint
|
|
08 Apr 2019 |
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
|
|
08 Apr 2019 |
Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
|
|
08 Apr 2019 |
Hope Medicine announced global license agreement with Bayer AG to advance the development and commercialization of the monoclonal antibody directed against prolactin (PRL) receptor
|
|
08 Apr 2019 |
SanBio Announces SB623 Regenerative Cell Therapy for Traumatic Brain Injury Has Received Ministry of Health, Labour and Welfare (MHLW) Sakigake Designation
|
|
08 Apr 2019 |
Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration
|
|
08 Apr 2019 |
Celltrion Partners with the Canadian Biotech Company, iProgen Biotech to Develop a Series of Novel ADCs
|
|
06 Apr 2019 |
Acceleron Discontinues Development of Phase 1 Molecule ACE-2494
|
|
06 Apr 2019 |
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
|
|
05 Apr 2019 |
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
|
|
05 Apr 2019 |
Merrimack Discontinues Development of MM-310
|
|
05 Apr 2019 |
Dystrogen Therapeutics Announces That Gene Therapy Successfully Cuts Off Production of Neuron-Destroying Protein in Huntington's Disease
|
|
05 Apr 2019 |
AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia
|
|
05 Apr 2019 |
Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU
|
|
05 Apr 2019 |
NIH begins first-in-human trial of a universal influenza vaccine candidate
|
